POLYMORPHISMS IN CACHEXIA PREDICT CLINICAL OUTCOMES OF COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN AND BEVACIZUMAB

摘要

Methods are provided for treating colorectal cancer patients with a therapy comprising irinotecan and bevacizumab. The methods entail administering the therapy to the patient if the patient has specific rs1792689, rs2268753, rs17776182, rs7570532 and/or rs4946935 polymorphisms.